Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VM2L
|
|||
| Former ID |
DAP001023
|
|||
| Drug Name |
Zoledronate
|
|||
| Synonyms |
Aclasta; Reclast; ZOL; Zometa; Novartis brand of zoledronic acid; Zoledronic acid; Zometa Concentrate; Bisphosphonate 3; CGP 42446; CGP 42446A; Aclasta (TN); CGP 42'446; CGP-42446; KS-1132; Reclast (TN); Zoledronic acid (INN); Zoledronic acid [USAN:INN]; Zomera (TN); Zometa (Novartis); Zometa (TN); CGP-42'446; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypercalcaemia [ICD-11: 5B91.0; ICD-9: 275.42] | Approved | [1] | |
| Therapeutic Class |
Bone Density Conservation Agents
|
|||
| Company |
Norvatis Phamaceuticals Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C5H10N2O7P2
|
|||
| Canonical SMILES |
C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
|
|||
| InChI |
1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
|
|||
| InChIKey |
XRASPMIURGNCCH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 118072-93-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
536160, 6436371, 7891233, 7980916, 8192311, 10318362, 10318375, 10318390, 10318944, 11528905, 14824151, 25819963, 29215499, 29215500, 43125267, 46507310, 46513035, 50473172, 53788750, 53801236, 56311814, 56436259, 56479320, 57317038, 81092860, 85174457, 87457600, 89736141, 92308965, 92712542, 93166450, 93167152, 96025372, 99343600, 99343604, 99437087, 99455519, 103240897, 104342928, 109692939, 117626547, 118048654, 124757161, 125163965, 125338822, 126592903, 126625470, 126656631, 126667014, 127324075
|
|||
| ChEBI ID |
CHEBI:46557
|
|||
| ADReCS Drug ID | BADD_D02392 | |||
| SuperDrug ATC ID |
M05BA08
|
|||
| SuperDrug CAS ID |
cas=118072938
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Geranyltranstransferase (FDPS) | Target Info | Modulator | [2] |
| BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
| Superpathway of cholesterol biosynthesis | ||||
| Trans, trans-farnesyl diphosphate biosynthesis | ||||
| Geranylgeranyldiphosphate biosynthesis | ||||
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Influenza A | ||||
| HTLV-I infection | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| Reactome | Cholesterol biosynthesis | |||
| Activation of gene expression by SREBF (SREBP) | ||||
| WikiPathways | Activation of Gene Expression by SREBP (SREBF) | |||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.